Home Cart Sign in  
Chemical Structure| 358721-70-7 Chemical Structure| 358721-70-7

Structure of UBCS039
CAS No.: 358721-70-7

Chemical Structure| 358721-70-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UBCS039 is a specific Sirtuin 6 activator which showed robust activating effects on Sirt6-dependent H3K18ac deacetylation of both full-length histone proteins and complete HeLa nucleosomes.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UBCS039

CAS No. :358721-70-7
Formula : C16H13N3
M.W : 247.29
SMILES Code : C1(NC2=CC=CC=C2N3C=CC=C13)C4=CN=CC=C4
MDL No. :MFCD00206184
InChI Key :BSOBGTYXYGHUTD-UHFFFAOYSA-N
Pubchem ID :2803797

Safety of UBCS039

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of UBCS039

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa epithelial cervix carcinoma 75 µM UBCS039 induced deacetylation of histone H3K9 PMC6155207
H1299 non-small cell lung cancer 75 µM UBCS039 induced a time-dependent deacetylation of histone H3K9 PMC6155207
HCT116 colon carcinoma 75 µM UBCS039 induced deacetylation of histone H3K9 PMC6155207
HT1080 human fibrosarcoma 75 µM UBCS039 triggered deacetylation of histone H3K56 PMC6155207
BMDM cells 150 μM 24 h To investigate the effect of SIRT6 activation on M1/M2 phenotype shift in macrophages, the results showed that UBCS039 treatment could shift macrophages from M1 to M2 phenotype. PMC8672560
RAW264.7 cells 150 μM 24 h To investigate the effect of SIRT6 activation on M1/M2 phenotype shift in macrophages, the results showed that UBCS039 treatment could shift macrophages from M1 to M2 phenotype. PMC8672560
ZAS-stimulated podocytes 100 µM 4 h Treatment with UBCS039 preserved the expression of podocyte-specific proteins (podocin, nephrin, and podocalyxin) and significantly inhibited the protein expression of β-catenin and its downstream gene products, including Snail1 and Twist. PMC10770168
Mouse platelets 100 μM 30 min UBCS039 pretreatment significantly inhibited thrombin-induced platelet aggregation. PMC10766690
H9c2 cells 100 μM 24 h UBCS039 reversed the inhibitory effect of D-galactose on cell proliferation and reduced the apoptosis rate. PMC9792202

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.04mL

0.81mL

0.40mL

20.22mL

4.04mL

2.02mL

40.44mL

8.09mL

4.04mL

References

 

Historical Records

Categories